CONNIE LEANZA: Open Payments
NPI 1205921152 · TULLAHOMA, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,000 in 98 payments from 19 companies in 2025. Trend: 2023 $1,310 · 2024 $1,283 · 2025 $2,000
Food & beverage: $2,000
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 18 | $466 |
| GlaxoSmithKline, LLC. | 18 | $275 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $230 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $166 |
| Verona Pharma, Inc. | 8 | $159 |
| GENZYME CORPORATION | 8 | $153 |
| Avadel CNS Pharmaceuticals, LLC | 4 | $119 |
| Regeneron Healthcare Solutions, Inc. | 5 | $89 |
| Electromed, Inc. | 6 | $66 |
| Grifols USA, LLC | 2 | $49 |
Products named: DUPIXENT, NUCALA, OFEV, GLASSIA, Ohtuvayre, FASENRA, LUMRYZ, TRELEGY ELLIPTA.
Industry payments across TN — which companies pay providers there.
